Literature DB >> 27858666

Mass Spectrometry-Based Identification of Muscle-Associated and Muscle-Derived Proteomic Biomarkers of Dystrophinopathies.

Paul Dowling1, Ashling Holland1, Kay Ohlendieck1.   

Abstract

The optimization of large-scale screening procedures of pathological specimens by genomic, proteomic and metabolic methods has drastically increased the bioanalytical capability for swiftly identifying novel biomarkers of inherited disorders, such as neuromuscular diseases. X-linked muscular dystrophy represents the most frequently inherited muscle disease and is characterized by primary abnormalities in the membrane cytoskeletal protein dystrophin. Mass spectrometry-based proteomics has been widely employed for the systematic analysis of dystrophin-deficient muscle tissues, using patient samples and animal models of dystrophinopathy. Both, gel-based methods and label-free mass spectrometric techniques have been applied in comparative analyses and established a large number of altered proteins that are associated with muscle contraction, energy metabolism, ion homeostasis, cellular signaling, the cytoskeleton, the extracellular matrix and the cellular stress response. Although these new indicators of muscular dystrophy have increased our general understanding of the molecular pathogenesis of dystrophinopathy, their application as new diagnostic or prognostic biomarkers would require the undesirable usage of invasive methodology. Hence, to reduce the need for diagnostic muscle biopsy procedures, more recent efforts have focused on the proteomic screening of suitable body fluids, such as plasma, serum or urine, for the identification of changed concentration levels of muscle-derived peptides, protein fragments or intact proteins. The occurrence of muscular dystrophy-related protein species in biofluids will be extremely helpful for the future development of cost-effective and non-invasive diagnostic procedures. Novel biomarker signatures of dystrophinopathies will be indispensible for the swift evaluation of innovative therapeutic approaches, such as exon skipping, codon-read-through or stem cell therapy.

Entities:  

Year:  2014        PMID: 27858666

Source DB:  PubMed          Journal:  J Neuromuscul Dis


  10 in total

Review 1.  Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials.

Authors:  Pierre G Carlier; Benjamin Marty; Olivier Scheidegger; Paulo Loureiro de Sousa; Pierre-Yves Baudin; Eduard Snezhko; Dmitry Vlodavets
Journal:  J Neuromuscul Dis       Date:  2016-03-03

Review 2.  Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy.

Authors:  Kay Ohlendieck; Dieter Swandulla
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 4.458

3.  Concurrent Label-Free Mass Spectrometric Analysis of Dystrophin Isoform Dp427 and the Myofibrosis Marker Collagen in Crude Extracts from mdx-4cv Skeletal Muscles.

Authors:  Sandra Murphy; Margit Zweyer; Rustam R Mundegar; Michael Henry; Paula Meleady; Dieter Swandulla; Kay Ohlendieck
Journal:  Proteomes       Date:  2015-09-16

4.  Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy.

Authors:  Sandra Murphy; Paul Dowling; Margit Zweyer; Michael Henry; Paula Meleady; Rustam R Mundegar; Dieter Swandulla; Kay Ohlendieck
Journal:  Int J Mol Med       Date:  2017-04-18       Impact factor: 4.101

5.  Proteomic identification of elevated saliva kallikrein levels in the mdx-4cv mouse model of Duchenne muscular dystrophy.

Authors:  Sandra Murphy; Margit Zweyer; Rustam R Mundegar; Dieter Swandulla; Kay Ohlendieck
Journal:  Biochem Biophys Rep       Date:  2018-05-30

6.  Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.

Authors:  Anna M L Coenen-Stass; Graham McClorey; Raquel Manzano; Corinne A Betts; Alison Blain; Amer F Saleh; Michael J Gait; Hanns Lochmüller; Matthew J A Wood; Thomas C Roberts
Journal:  Sci Rep       Date:  2015-11-23       Impact factor: 4.379

7.  Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.

Authors:  Peter M Burch; Oksana Pogoryelova; Richard Goldstein; Donald Bennett; Michela Guglieri; Volker Straub; Kate Bushby; Hanns Lochmüller; Carl Morris
Journal:  J Neuromuscul Dis       Date:  2015-09-02

Review 8.  The biochemical and mass spectrometric profiling of the dystrophin complexome from skeletal muscle.

Authors:  Sandra Murphy; Kay Ohlendieck
Journal:  Comput Struct Biotechnol J       Date:  2015-11-26       Impact factor: 7.271

9.  Mass spectrometric identification of dystrophin, the protein product of the Duchenne muscular dystrophy gene, in distinct muscle surface membranes.

Authors:  Sandra Murphy; Kay Ohlendieck
Journal:  Int J Mol Med       Date:  2017-07-27       Impact factor: 4.101

10.  Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy.

Authors:  Kristin Strandberg; Burcu Ayoglu; Andreas Roos; Mojgan Reza; Erik Niks; Mirko Signorelli; Erik Fasterius; Fredrik Pontén; Hanns Lochmüller; Joana Domingos; Pierpaolo Ala; Francesco Muntoni; Annemieke Aartsma-Rus; Pietro Spitali; Peter Nilsson; Cristina Al-Khalili Szigyarto
Journal:  J Neuromuscul Dis       Date:  2020
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.